Giovanni Battista Dell’isola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Giovanni Battista Dell’isola has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Alberto Verrotti
Department of Pediatrics, University of Perugia, Perugia, Italy
7 shared publicationsGiuseppe Di Cara
Department of Pediatrics, University of Perugia, Perugia, Italy
7 shared publications- Alberto Verrotti
Department of Pediatrics, University of Perugia, Perugia, Italy
6 shared publications - Antonella Fattorusso
Pediatric Unit, Hospital Santa Maria Della Misericordia, Perugia, Italy
5 shared publications Elisabetta Mencaroni
Pediatric Clinic, Department of Surgical and Biomedical Sciences, University of Perugia, Perugia, Italy
4 shared publications- Giuseppe Di Cara
Department of Medicine and Surgery, University of Perugia, Perugia, Italy
4 shared publications
Latest Publications
- 14 April 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 138, 133-138
Childhood absence epilepsy and developmental coordination disorder: an intriguing comorbidity
- 14 April 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 138, 133-138
Childhood absence epilepsy and developmental coordination disorder: an intriguing comorbidity
- 5 December 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 249, 108673
Clinical, etiological, and therapeutic profile of early-onset absence seizures: A case series analysis
- 5 December 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 249, 108673
Clinical, etiological, and therapeutic profile of early-onset absence seizures: A case series analysis
- Open Access
- 30 October 2024
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (12) , 7648-7649
Correction to: CDKL5 deficiency-related neurodevelopmental disorders: a multi-center cohort study in Italy
- 30 October 2024
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (12) , 7648-7649
Open AccessCorrection to: CDKL5 deficiency-related neurodevelopmental disorders: a multi-center cohort study in Italy
- Open Access
- 14 June 2024
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (8) , 5368-5377
CDKL5 deficiency-related neurodevelopmental disorders: a multi-center cohort study in Italy
CDKL5 deficiency disorder (CDD) is a complex clinical condition resulting from non-functional or absent CDKL5 protein, a serine–threonine kinase pivotal for neural maturation and synaptogenesis. The disorder manifests primarily as developmental epileptic encephalopathy, with associated neurological phenotypes, such as hypotonia, movement disorders, visual impairment, and gastrointestinal issues. Its prevalence is estimated at 1 in 40,000–60,000 live births, and it is more prevalent in females due to the lethality of germline mutations in males during fetal development. This Italian multi-center observational study focused on 34 patients with CDKL5-related epileptic encephalopathy, aiming to enhance the understanding of the clinical and molecular aspects of CDD. The study, conducted across 14 pediatric neurology tertiary care centers in Italy, covered various aspects, including phenotypic presentations, seizure types, EEG patterns, treatments, neuroimaging findings, severity of psychomotor delay, and variant-phenotype correlations. The results highlighted the heterogeneity of seizure patterns, with hypermotor-tonic-spasms sequence seizures (HTSS) noted in 17.6% of patients. The study revealed a lack of clear genotype–phenotype correlation within the cohort. The presence of HTSS or HTSS-like at onset resulted a negative prognostic factor for the presence of daily seizures at long-term follow-up in CDD patients. Despite extensive polypharmacotherapy, including medications such as valproic acid, clobazam, cannabidiol, and others, sustained seizure freedom proved elusive, affirming the inherent drug-resistant nature of CDD. The findings underscored the need for further research to explore response rates to different treatments and the potential role of non-pharmacological interventions in managing this challenging disorder.
- 14 June 2024
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (8) , 5368-5377
Open AccessCDKL5 deficiency-related neurodevelopmental disorders: a multi-center cohort study in Italy
CDKL5 deficiency disorder (CDD) is a complex clinical condition resulting from non-functional or absent CDKL5 protein, a serine–threonine kinase pivotal for neural maturation and synaptogenesis. The disorder manifests primarily as developmental epileptic encephalopathy, with associated neurological phenotypes, such as hypotonia, movement disorders, visual impairment, and gastrointestinal issues. Its prevalence is estimated at 1 in 40,000–60,000 live births, and it is more prevalent in females due to the lethality of germline mutations in males during fetal development. This Italian multi-center observational study focused on 34 patients with CDKL5-related epileptic encephalopathy, aiming to enhance the understanding of the clinical and molecular aspects of CDD. The study, conducted across 14 pediatric neurology tertiary care centers in Italy, covered various aspects, including phenotypic presentations, seizure types, EEG patterns, treatments, neuroimaging findings, severity of psychomotor delay, and variant-phenotype correlations. The results highlighted the heterogeneity of seizure patterns, with hypermotor-tonic-spasms sequence seizures (HTSS) noted in 17.6% of patients. The study revealed a lack of clear genotype–phenotype correlation within the cohort. The presence of HTSS or HTSS-like at onset resulted a negative prognostic factor for the presence of daily seizures at long-term follow-up in CDD patients. Despite extensive polypharmacotherapy, including medications such as valproic acid, clobazam, cannabidiol, and others, sustained seizure freedom proved elusive, affirming the inherent drug-resistant nature of CDD. The findings underscored the need for further research to explore response rates to different treatments and the potential role of non-pharmacological interventions in managing this challenging disorder.
- Open Access
- 15 May 2024
- Published by Savvy Science Publisher in International Journal of Pediatrics and Child Health
- Vol. 12, 57-65
The Effectiveness of Glycopyrronium in Drooling Managment: A Scoping Review Protocol
The management of pediatric drooling presents challenges requiring tailored therapeutic approaches. This scoping review examines the efficacy and safety of glycopyrronium in addressing drooling across diverse pediatric populations. Glycopyrronium, an anticholinergic medication, inhibits salivary gland activity, offering promise in managing drooling. Clinical trials and observational studies consistently demonstrate its effectiveness, particularly in children with neurological disabilities like cerebral palsy. Notably, glycopyrronium exhibits efficacy even at lower dosages, emphasizing personalized treatment. However, potential side effects such as dry mouth and vision changes necessitate careful monitoring. Future research should explore predictors of treatment response and include diverse patient populations to optimize management strategies. Overall, glycopyrronium emerges as a valuable therapeutic option for pediatric drooling, improving quality of life for affected children. This review underscores the importance of tailored approaches and highlights the need for further research to enhance outcomes in pediatric drooling management.
- 15 May 2024
- Published by Savvy Science Publisher in International Journal of Pediatrics and Child Health
- Vol. 12, 57-65
Open AccessThe Effectiveness of Glycopyrronium in Drooling Managment: A Scoping Review Protocol
The management of pediatric drooling presents challenges requiring tailored therapeutic approaches. This scoping review examines the efficacy and safety of glycopyrronium in addressing drooling across diverse pediatric populations. Glycopyrronium, an anticholinergic medication, inhibits salivary gland activity, offering promise in managing drooling. Clinical trials and observational studies consistently demonstrate its effectiveness, particularly in children with neurological disabilities like cerebral palsy. Notably, glycopyrronium exhibits efficacy even at lower dosages, emphasizing personalized treatment. However, potential side effects such as dry mouth and vision changes necessitate careful monitoring. Future research should explore predictors of treatment response and include diverse patient populations to optimize management strategies. Overall, glycopyrronium emerges as a valuable therapeutic option for pediatric drooling, improving quality of life for affected children. This review underscores the importance of tailored approaches and highlights the need for further research to enhance outcomes in pediatric drooling management.
- Open Access
- 3 January 2024
- Published by MDPI AG in Pediatric Reports
- Vol. 16 (1) , 21-25
Current Overview of CDKL-5 Deficiency Disorder Treatment
CDKL5 deficiency disorder (CDD) is a complex of clinical symptoms resulting from the presence of non-functional or absent CDKL5 protein, a serine–threonine kinase involved in neural maturation and synaptogenesis
- 3 January 2024
- Published by MDPI AG in Pediatric Reports
- Vol. 16 (1) , 21-25
Open AccessCurrent Overview of CDKL-5 Deficiency Disorder Treatment
CDKL5 deficiency disorder (CDD) is a complex of clinical symptoms resulting from the presence of non-functional or absent CDKL5 protein, a serine–threonine kinase involved in neural maturation and synaptogenesis
- Open Access
- 17 January 2023
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 19 (7) , 635-643
Clinical spectrum and currently available treatment of type I interferonopathy Aicardi–Goutières syndrome
Background: Aicardi–Goutières syndrome (AGS) is a genetically determined disorder with a variable phenotype. Since the original description of AGS, advances in gene sequencing techniques have resulted in a significant broadening of the phenotypic spectrum associated with AGS genes, and new clinical pictures have emerged beyond the classic presentation. The aim of this review is to provide a comprehensive analysis of the clinical spectrum of AGS and report currently available treatments and new immunosuppressive strategies. Data sources: Literature reviews and original research articles were collected from databases, including PubMed and ClinicalTrials.gov. Relevant articles about AGS were included. Results: The involvement of the nervous system certainly represents the major cause of mortality and morbidity in AGS patients. However, other clinical manifestations, such as chilblains, hepatosplenomegaly, and hematological disturbances, may lead to the diagnosis and considerably impact the prognosis and overall quality of life of these patients. Therapeutic approaches of AGS are limited to interventions aimed at specific symptoms and the management of multiple comorbidities. However, advances in understanding the pathogenesis of AGS could open new and more effective therapies. Conclusions: The over-activation of innate immunity due to upregulated interferon production plays a critical role in AGS, leading to multi-organ damage with the main involvement of the central nervous system. To date, there is no specific and effective treatment for AGS. New drugs specifically targeting the interferon pathway may bring new hope to AGS patients.
- 17 January 2023
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 19 (7) , 635-643
Open AccessClinical spectrum and currently available treatment of type I interferonopathy Aicardi–Goutières syndrome
Background: Aicardi–Goutières syndrome (AGS) is a genetically determined disorder with a variable phenotype. Since the original description of AGS, advances in gene sequencing techniques have resulted in a significant broadening of the phenotypic spectrum associated with AGS genes, and new clinical pictures have emerged beyond the classic presentation. The aim of this review is to provide a comprehensive analysis of the clinical spectrum of AGS and report currently available treatments and new immunosuppressive strategies. Data sources: Literature reviews and original research articles were collected from databases, including PubMed and ClinicalTrials.gov. Relevant articles about AGS were included. Results: The involvement of the nervous system certainly represents the major cause of mortality and morbidity in AGS patients. However, other clinical manifestations, such as chilblains, hepatosplenomegaly, and hematological disturbances, may lead to the diagnosis and considerably impact the prognosis and overall quality of life of these patients. Therapeutic approaches of AGS are limited to interventions aimed at specific symptoms and the management of multiple comorbidities. However, advances in understanding the pathogenesis of AGS could open new and more effective therapies. Conclusions: The over-activation of innate immunity due to upregulated interferon production plays a critical role in AGS, leading to multi-organ damage with the main involvement of the central nervous system. To date, there is no specific and effective treatment for AGS. New drugs specifically targeting the interferon pathway may bring new hope to AGS patients.
- 17 September 2022
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 102, 32-35
Clinical and electroencephalographic features of epilepsy in patients with triple X syndrome: A case series
- 17 September 2022
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 102, 32-35
Clinical and electroencephalographic features of epilepsy in patients with triple X syndrome: A case series
- Open Access
- 17 August 2022
- Published by Springer Nature in BMC Medical Genomics
- Vol. 15 (1) , 1-5
Expanding the genetic and clinical characteristics of Protocadherin 19 gene mutations
Background: PCDH19-related epilepsy is a rare X-linked type of epilepsy caused by genomic variants of the Protocadherin 19 (PCDH19) gene. The clinical characteristics of PCDH19-related epilepsy are epileptic and non-epileptic symptoms with highly variable severity among patients. Case presentation: We present a case of a 4-year old female with PCDH19-related epilepsycaused by new variants in the PCDH19 gene. Our patient was admitted for the first time at the age of 12 months for seizure clusters arising under condition of apyrexia. The electroencephalography (EEG) showed frontal paroxysmal activity. The genetic analysis identified the two variants c.1006G > A (p.Val336Met) and c.1014C > A (p.Asp338Glu) in the gene PCDH19. The patient was treated with Carbamazepine and Clonazepam achieving the disappearance of seizures. During the follow-up, the neurological examination was persistently normal with neither cognitive impairment nor behavior disturbances. From 2 years of age EEG controls were persistently normal. Conclusion: This patient presents two novel variants of the PCDH19 gene associated with a mild form of epilepsy with normal cognitive development with an apparently better prognosis. According to our experience, the dual therapy with Carbamazepine and Clonazepam has led to a good control of seizures.
- 17 August 2022
- Published by Springer Nature in BMC Medical Genomics
- Vol. 15 (1) , 1-5
Open AccessExpanding the genetic and clinical characteristics of Protocadherin 19 gene mutations
Background: PCDH19-related epilepsy is a rare X-linked type of epilepsy caused by genomic variants of the Protocadherin 19 (PCDH19) gene. The clinical characteristics of PCDH19-related epilepsy are epileptic and non-epileptic symptoms with highly variable severity among patients. Case presentation: We present a case of a 4-year old female with PCDH19-related epilepsycaused by new variants in the PCDH19 gene. Our patient was admitted for the first time at the age of 12 months for seizure clusters arising under condition of apyrexia. The electroencephalography (EEG) showed frontal paroxysmal activity. The genetic analysis identified the two variants c.1006G > A (p.Val336Met) and c.1014C > A (p.Asp338Glu) in the gene PCDH19. The patient was treated with Carbamazepine and Clonazepam achieving the disappearance of seizures. During the follow-up, the neurological examination was persistently normal with neither cognitive impairment nor behavior disturbances. From 2 years of age EEG controls were persistently normal. Conclusion: This patient presents two novel variants of the PCDH19 gene associated with a mild form of epilepsy with normal cognitive development with an apparently better prognosis. According to our experience, the dual therapy with Carbamazepine and Clonazepam has led to a good control of seizures.
- Open Access
- 17 January 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12, 780053
The Broad Clinical Spectrum of Epilepsies Associated With Protocadherin 19 Gene Mutation
Protocadherin 19 (PCDH19) gene is one of the most common genes involved in epilepsy syndromes. According to literature data PCDH19 is among the 6 genes most involved in genetic epilepsies. PCDH19 is located on chromosome Xq22.1 and is involved in neuronal connections and signal transduction. The most frequent clinical expression of PCDH19 mutation is epilepsy and mental retardation limited to female (EFMR) characterized by epileptic and non-epileptic symptoms affecting mainly females. However, the phenotypic spectrum of these mutations is considerably variable from genetic epilepsy with febrile seizure plus to epileptic encephalopathies. The peculiar exclusive involvement of females seems to be caused by a cellular interference in heterozygosity, however, affected mosaic-males have been reported. Seizure types range from focal seizure to generalized tonic-clonic, tonic, atonic, absences, and myoclonic jerks. Treatment of PCDH19-related epilepsy is limited by drug resistance and by the absence of specific treatment indications. However, seizures become less severe with adolescence and some patients may even become seizure-free. Non-epileptic symptoms represent the main disabilities of adult patients with PCDH19 mutation. This review aims to analyze the highly variable phenotypic expression of PCDH19 gene mutation associated with epilepsy.
- 17 January 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12, 780053
Open AccessThe Broad Clinical Spectrum of Epilepsies Associated With Protocadherin 19 Gene Mutation
Protocadherin 19 (PCDH19) gene is one of the most common genes involved in epilepsy syndromes. According to literature data PCDH19 is among the 6 genes most involved in genetic epilepsies. PCDH19 is located on chromosome Xq22.1 and is involved in neuronal connections and signal transduction. The most frequent clinical expression of PCDH19 mutation is epilepsy and mental retardation limited to female (EFMR) characterized by epileptic and non-epileptic symptoms affecting mainly females. However, the phenotypic spectrum of these mutations is considerably variable from genetic epilepsy with febrile seizure plus to epileptic encephalopathies. The peculiar exclusive involvement of females seems to be caused by a cellular interference in heterozygosity, however, affected mosaic-males have been reported. Seizure types range from focal seizure to generalized tonic-clonic, tonic, atonic, absences, and myoclonic jerks. Treatment of PCDH19-related epilepsy is limited by drug resistance and by the absence of specific treatment indications. However, seizures become less severe with adolescence and some patients may even become seizure-free. Non-epileptic symptoms represent the main disabilities of adult patients with PCDH19 mutation. This review aims to analyze the highly variable phenotypic expression of PCDH19 gene mutation associated with epilepsy.